Reporting Season: Healthcare Sector Preview

About the author:

Dr Derek Jellinek
Author name:
By Dr Derek Jellinek
Job title:
Senior Analyst
Date posted:
10 February 2021, 9:00 AM
Sectors Covered:
Healthcare

Key picks in the Healthcare sector and their upcoming catalysts:

Watch

 

Top healthcare sector picks

We highlight our expectations for each of the stocks ahead of their upcoming results. Please note, ResMed has already reported it's results.

ResMed (RMD)

2Q was solid and above expectations, underpinned by high single digit revenue growth and expanding GM, with good cost control helping to drive operating leverage.

Sonic Healthcare (SHL)

We expect a strong result, underpinned by COVID testing across all key geographies more than offsetting weakness in the base business (ie non-COVID testing).

Virtus Health (VRT)

We are forecasting NPAT of A$16.8m up 19.1% on pcp. There are no consensus 1H forecasts. We expect to hear positive commentary around cycle volumes remaining steady in 2HFY21.

Monash IVF (MVF)

We are forecasting 1HFY21 NPAT before non-regular items of A$11m.

Volpara (VPH)

We are forecasting NPAT of A$16.8m up 19.1% on pcp. There are no consensus 1H forecasts. We expect to hear positive commentary around cycle volumes remaining steady in 2HFY21.

Pro Medicus (PME)

We expect a solid result with EBITDA up >20% to A$22.5m, reflecting margin expansion driven by lower opex due to travel restrictions and full period contributions and setup fees from a number of new recent contracts

Mach7 Technologies (M7T)

Our forecast EBITDA is A$1.7m for 1HFY21.

Find out more

You can find further detailed analysis of company results this reporting season by browsing our reporting season tag, and view a full list of upcoming results on our Reporting Season Calendar.

Reporting Season Calendar

If you would like access or more information, please contact your adviser or nearest Morgans office.

Request a call  Find local branch

Need access to our research?

You are also welcome to start a two-week trial of our online platform, which provides access to detailed market analysis and insights, provided by our award-winning research team

Create trial account 

Disclaimer: The information contained in this report is provided to you by Morgans Financial Limited as general advice only, and is made without consideration of an individual's relevant personal circumstances. Morgans Financial Limited ABN 49 010 669 726, its related bodies corporate, directors and officers, employees, authorised representatives and agents (“Morgans”) do not accept any liability for any loss or damage arising from or in connection with any action taken or not taken on the basis of information contained in this report, or for any errors or omissions contained within. It is recommended that any persons who wish to act upon this report consult with their Morgans investment adviser before doing so.

  • Print this page
  • Copy Link